July 30, 2025
Immutep Quarterly Activities Report Q4 FY25
July 29, 2025
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer
July 28, 2025
Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
June 23, 2025
Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases
May 26, 2025
Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
May 15, 2025
Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer
April 23, 2025
Investor Update – April 2025
November 26, 2024
Investor Update – November 2024
February 21, 2024
Investor Update – February 2024
Baird – FY4Q25: Ongoing Enrollment for Phase 3 1L NSCLC Study; Broad Progress; Rated OP, US$7 PT (Analyst: Colleen M. Kusy, CFA)
July 17, 2025
Wilsons – IMP761 | Can I&I success fund I-O upside? Maintain Overweight, A$1.20 TP (Analysts: Dr Shane Storey and Dr Lisa Worley)
July 11, 2025
Jefferies – Efti/Pembro Looks Good vs. Other Combos and Other Therapies in NSCLC and HNSCC; Rated BUY, PT A$2.10 (Analyst: Dr David Stanton)
Baird – Updated Phase 1 Safety/Efficacy HV Data for IMP761 (LAG-3) for Autoimmune; Rated OP, US$7 PT (Analyst: Colleen M. Kusy, CFA)
Canaccord Genuity – IMP761 PhI shows good safety and T cell suppression; BUY, A$0.98 PT (Analyst: Elyse Shapiro)
May 16, 2025
Maxim – Positive Response Data from INSIGHT-003 in 1L NSCLC; Bodes Well for Ongoing P3 Pivotal TACTI-004 Study – Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)
Please fill out the registration form below to receive updates and announcements by e-mail.
*Required
I/We authorise you to act in accordance with my/our instructions set out above.
The privacy policy was read and accepted.
